RT Journal Article
SR Electronic
T1 Sensitivity of wastewater-based epidemiology for detection of SARS-CoV-2 RNA in a low prevalence setting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.24.21258577
DO 10.1101/2021.08.24.21258577
A1 Hewitt, Joanne
A1 Trowsdale, Sam
A1 Armstrong, Bridget
A1 Chapman, Joanne R.
A1 Carter, Kirsten
A1 Croucher, Dawn
A1 Billiau, Cassandra
A1 Sim, Rosemary
A1 Gilpin, Brent J.
YR 2021
UL http://medrxiv.org/content/early/2021/08/26/2021.08.24.21258577.abstract
AB To assist public health responses to COVID-19, wastewater-based epidemiology (WBE) is being utilised internationally to monitor SARS-CoV-2 infections at the community level. However, questions remain regarding the sensitivity of WBE and its use in low prevalence settings. In this study, we estimated the total number of COVID-19 cases required for detection of SARS-CoV-2 RNA in wastewater. To do this, we leveraged a unique situation where, over a 4-month period, all symptomatic and asymptomatic cases, in a population of approximately 120,000, were precisely known and mainly located in a single managed isolation and quarantine facility (MIQF) building. From 9 July to 6 November 2020, 24-hr composite wastewater samples (n = 113) were collected daily from the sewer outside the MIQF, and from the municipal wastewater treatment plant (WWTP) located 5 km downstream. New daily COVID-19 cases at the MIQF ranged from 0 to 17, and for most of the study period there were no cases outside the MIQF identified. SARS-CoV-2 RNA was detected in 54.0% (61/113) at the WWTP, compared to 95.6% (108/113) at the MIQF. We used logistic regression to estimate the shedding of SARS-CoV-2 RNA into wastewater based on four infectious shedding models. With a total of 5 and 10 COVID-19 infectious cases per 100,000 population (0.005 % and 0.01% prevalence) the predicated probability of SARS-CoV-2 RNA detection at the WWTP was estimated to be 28 and 41%, respectively. When a more realistic proportional shedding model was used, this increased to 58% and 87% for 5 and 10 cases, respectively. In other words, when 10 individuals were actively shedding SARS-CoV-2 RNA in a catchment of 100,000 individuals, there was a high likelihood of detecting viral RNA in wastewater. SARS-CoV-2 RNA detections at the WWTP were associated with increasing COVID-19 cases. Our results show that WBE provides a reliable and sensitive platform for detecting infections at the community scale, even when case prevalence is low, and can be of use as an early warning system for community outbreaks.HighlightsOver 4 months, all 0-17 new daily cases in one quarantine building, catchment 120,000 populationWastewater tested daily at quarantine building and downstream wastewater treatment plant, WWTPSARS-CoV-2 RNA detected in 95.6% (108/113) at the MIQF and 54.0% (61/113) at the WWTPSARS-CoV-2 RNA detections at the WWTP associated with increasing COVID-19 casesProbability of SARS-CoV-2 RNA detection of 87% with 0.01% total case prevalenceCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNot a clinical trial, wastewater testingFunding StatementThis work was supported by the Ministry of Business & Innovation COVID-19 Innovation Acceleration Fund, grant number CIAF-0840. The funders had no role in study design; collection, analysis, and interpretation of data; manuscript writing or the submission process.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:New Zealand Health and Disability Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the paper